Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...

Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...

Compounding pharmacies have been allowed to make their knockoff versions of the drugs since ... But with the outsized demand ...

Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies ...

Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...

Millions of Americans rely on a new class of medications to manage chronic conditions like diabetes and obesity, with ...

Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...

CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

Stacy Hightower, CPhT, FAPC, of Las Colinas Pharmacy Compounding & Wellness in Irving, Texas, was honored as PCCA's inaugural ...